Matthew K. Fust, Director at Neumora Therapeutics, Inc. (NMRA), sold 43,576 shares at $17.01 ($742K) on 2024-10-17, disclosed to the SEC on 2024-10-18.
Scheduled sale ($742k) by Director under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $17.01 | 7,739 | $132K | 17.7% |
| 2 | $17.01 | 7,739 | $132K | 17.7% |
| 3 | $17.03 | 14,049 | $239K | 32.3% |
| 4 | $17.03 | 14,049 | $239K | 32.3% |
| Total | $17.02 avg | 43,576 | $742K | 100% |
| Filing → |
| RARE | SELL | 2024-03-11 | $859K | — | Filing → |
| CRNX | SELL | 2022-07-15 | $119K | — | Filing → |
| ATRA | SELL | 2021-11-05 | $260K | — | Filing → |